Trade

with

Keryx Biopharmaceuticals Inc
(NASDAQ: KERX)
AdChoices
16.01
+0.09
+0.57%
After Hours :
16.00
-0.01
-0.06%

Open

15.61

Previous Close

15.92

Volume (Avg)

1.18M (2.46M)

Day's Range

15.54-16.28

52Wk Range

10.01-18.48

Market Cap.

1.47B

Dividend Rate ( Yield )

-

Beta

3.17

Shares Outstanding

91.97M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 7.00M

    • Net Income

    • -46.73M

    • Market Cap.

    • 1.47B

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -692.63

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 3.17

    • Forward P/E

    • -104.17

    • Price/Sales

    • 136.99

    • Price/Book Value

    • 11.76

    • Price/Cash flow

    • -25.45

      • EBITDA

      • -47.03M

      • Return on Capital %

      • -60.76

      • Return on Equity %

      • -70.11

      • Return on Assets %

      • -60.76

      • Book Value/Share

      • 1.35

      • Shares Outstanding

      • 91.97M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • 25.00

        • Credit Rating

        • -

        • Analysts

        • 5

        • EPS Estimate

        • -0.15

        • Cashflow Estimate

        • 1.16

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 0.00

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 40.40

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 82.75

            • Pre-Tax Margin

            • -692.63

            • 39.38

            • Net Profit Margin

            • -692.63

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 7.47

              • 2.92

              • Quick Ratio

              • 7.41

              • 2.35

              • Interest Coverage

              • -

              • 38.02

              • Leverage Ratio

              • 1.15

              • 2.21

              • Book Value/Share

              • 1.35

              • 4.75

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -19.31

                • 277.78

                • P/E Ratio 5-Year High

                • -22.97

                • 634.30

                • P/E Ratio 5-Year Low

                • -1.59

                • 124.82

                • Price/Sales Ratio

                • 133.33

                • 9.35

                • Price/Book Value

                • 11.47

                • 8.50

                • Price/Cash Flow Ratio

                • -25.45

                • 50.25

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -70.11

                    (-77.00)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -60.76

                    (-58.00)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -70.11

                    (-77.00)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • -

                  • 1.48

                  • Asset Turnover

                  • 0.09

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -47.08M
                  Operating Margin
                  -672.61
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -25.45
                  Ownership

                  Institutional Ownership

                  83.39%

                  Top 10 Institutions

                  51.30%

                  Mutual Fund Ownership

                  37.77%

                  Float

                  88.08%

                  5% / Insider Ownership

                  6.68%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity® Select Biotechnology Portfolio

                  •  

                    3,125,768

                  • 5.90

                  • 3.40

                  • Oak Ridge Small Cap Growth Fund

                  •  

                    2,094,900

                  • 51.11

                  • 2.28

                  • Franklin Biotechnology Discovery

                  •  

                    2,044,000

                  • 43.09

                  • 2.24

                  • Vanguard Small Cap Index

                  •  

                    1,594,916

                  • 90.96

                  • 1.74

                  • Vanguard Total Stock Mkt Idx

                  •  

                    1,493,420

                  • 0.00

                  • 1.63

                  • iShares Russell 2000 (AU)

                  •  

                    1,415,419

                  • -1.02

                  • 1.74

                  • SPDR® S&P Biotech ETF

                  •  

                    1,234,675

                  • 3.59

                  • 1.52

                  • Eagle Small Cap Growth Fund

                  •  

                    1,217,798

                  • -10.97

                  • 1.33

                  • Franklin Biotechnology Discovery Fund

                  •  

                    1,107,300

                  • 22.64

                  • 1.21

                  • UBS (Lux) EF Biotech (USD)

                  •  

                    1,079,996

                  • 0.00

                  • 1.18

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Vanguard Group, Inc.

                  •  

                    4,160,274

                  • +0.97%

                  • 4.53

                  • Deerfield Management Co

                  •  

                    3,884,409

                  • +176.84%

                  • 4.23

                  • Fidelity Management and Research Company

                  •  

                    3,766,433

                  • +4.19%

                  • 4.11

                  • Sectoral Asset Management Inc

                  •  

                    3,741,656

                  • +5.77%

                  • 4.08

                  • Camber Capital Management LLC

                  •  

                    3,000,000

                  • +140.00%

                  • 3.27

                  • Franklin Advisers, Inc.

                  •  

                    2,946,900

                  • -3.14%

                  • 3.21

                  • State Street Corp

                  •  

                    2,631,452

                  • -6.85%

                  • 2.87

                  • BlackRock Fund Advisors

                  •  

                    2,565,844

                  • -0.31%

                  • 2.80

                  • Oak Ridge Investments, LLC

                  •  

                    2,081,792

                  • +0.71%

                  • 2.27

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Distressed

                  Style

                  Small Growth

                  Keryx Biopharmaceuticals, Inc., was incorporated in Delaware in October 1998. The Company is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of re...morenal disease. It is developing ZerenexTM an oral, ferric iron-based compound. It has completed a U.S.-based Phase 3 clinical program for Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with chronic kidney disease, or CKD, on dialysis, conducted pursuant to a Special Protocol Assessment, or SPA, agreement with the U.S. Food and Drug Administration, or FDA. Its New Drug Application, or NDA, is currently under review by the FDA with an assigned Prescription Drug User Fee Act, or PDUFA. It has also completed a U.S.-based Phase 2 study of...more Zerenex for the management of elevated serum phosphorus levels and iron deficiency anemia in subjects with Stage 3 to 5 NDD-CKD. Currently, its only drug candidate is Zerenex. Its competitors include pharmaceutical companies and biotechnology companies, as well as universities and public and private research institutions.lessless

                  Key People

                  Ron Bentsur

                  CEO/Director

                  Michael P. Tarnok

                  Director/Chairman of the Board

                  James F. Oliviero

                  CFO/Chief Accounting Officer/Secretary/Treasurer

                  Greg Madison

                  COO/Executive VP

                  Jack Kaye

                  Director

                  • Keryx Biopharmaceuticals Inc

                  • 750 Lexington Avenue

                  • New York, NY 10022

                  • USA.Map

                  • Phone: +1 212 531-5965

                  • Fax: +1 212 531-5961

                  • keryx.com

                  Incorporated

                  1998

                  Employees

                  88

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: